September 20, 2014 10:58 AM ET

Pharmaceuticals

Company Overview of Theracos, Inc.

Company Overview

Theracos, Inc. operates as a pharmaceutical research and development company in the United States. It engages in developing and acquiring therapeutic agents, and supporting research programs in the disease areas of inflammation, metabolism, and depression. The company was founded in 2000 and is based in Marlborough, Massachusetts.

225 Cedar Hill Road

Suite 200

Marlborough, MA 01752

United States

Founded in 2000

Phone:

508-688-4221

Key Executives for Theracos, Inc.

Chief Executive Officer
Co-Founder and Director
Age: 67
Secretary and Director
Compensation as of Fiscal Year 2014.

Theracos, Inc. Key Developments

Theracos, Inc. Reports Positive Outcomes from 96-Week Phase 2 Study of THR1442, Highly Specific SGLT2 Inhibitor, for the Treatment of Type 2 Diabetes

Theracos, Inc. announced the results of a multinational 96-week Phase 2 study evaluating the efficacy and safety of the SGLT-2 inhibitor THR1442. The double-blinded, placebo-controlled study enrolled a total of 288 subjects with Type 2 diabetes from sites in the US, Mexico and Colombia and evaluated the efficacy of THR1442 compared to placebo as a monotherapy for the treatment of diabetes. The primary efficacy endpoint was change in HbA1c at week 24. Treatment with THR1442 resulted in a statistically significant lowering of HbA1c, relative to placebo, of 0.79%, a difference that increased to 1.02% following 96 weeks of treatment. The proportion of subjects achieving an HbA1c level of less than 7% following 24 weeks of treatment was 24% in the THR1442 arm versus 11% in the placebo arm. At 96 weeks of treatment, the proportion of subjects achieving an HbA1c level of less than 7% further improved to 31% in the THR1442 arm versus 11% in the placebo arm. Randomized subjects participating in the study included roughly 10% that were treatment naïve, equally distributed between the THR1442 and placebo arms. SGLT2 inhibitors as a class have been reported to increase the rate of genital mycotic infections, particularly among female subjects, for whom incidences approaching 20% have been recorded following treatment with other compounds in the class for durations similar to or shorter than that of this study. In this large trial, THR1442 produced no increase in genital infection rates relative to the placebo arm following 96 weeks of treatment. The overall genital infection rate was 2.13% in the placebo arm and 2.07% in the THR1442 arm at study conclusion. An approximately equal number of males and females were exposed to placebo or active agent, and urinary tract infection rates were higher in the placebo arm than in the THR1442 arm. The incidence of asymptomatic hypoglycemia was comparable in both the placebo and treatment arms and no severe hypoglycemic events were observed. Patients treated with THR1442 achieved meaningful and sustained reductions in both diastolic and systolic blood pressure, as well as significant and durable weight loss in this study.

Similar Private Companies By Industry

Company Name Region
Phytomedics, Inc. United States
EVS Glaucoma Therapeutics LLC United States
PreCision Dermatology, Inc. United States
Phoenix Biopharm Inc United States
Serum Technologies Holdings, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Theracos, Inc., please visit www.theracos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.